>سوق التحويل الجيني في أوروبا، النوع (التحويل الجيني المؤقت والتحويل الجيني المستقر)، الطرق (الطرق غير الفيروسية والطرق الفيروسية)، طرق التحويل الجيني باستخدام تقنية كريسبر (الطرق غير الفيروسية والطرق الفيروسية)، المنتجات (الكواشف والمجموعات والأجهزة والبرامج)، الكائن الحي (الخلايا الثديية والنباتات والفطريات والفيروسات والبكتيريا)، أنواع الجزيئات (الحمض النووي البلازميدي، الحمض النووي الريبي المتداخل الصغير (siRNA)، البروتينات، أوليجونوكليوتيدات الحمض النووي، مجمعات الريبوزوكليوبروتين (RNPs) وغيرها)، التطبيق (التطبيق المختبري، التطبيق الحيوي، الإنتاج البيولوجي، وغيرها)، المرحلة (البحث، ما قبل السريرية، المراحل السريرية والتجارية)، المستخدم النهائي (الشركات الصيدلانية الحيوية، منظمات أبحاث العقود (CROs)، منظمة التصنيع التعاقدي/منظمة تطوير وتصنيع العقود (CMOs/CDMOs)، الأوساط الأكاديمية والمستشفيات والمختبرات السريرية وغيرها)، قناة التوزيع (العطاء المباشر، مبيعات التجزئة وغيرها)، البلد (ألمانيا، فرنسا، إيطاليا، المملكة المتحدة، إسبانيا، سويسرا، روسيا، هولندا، بلجيكا، تركيا، بقية أوروبا) اتجاهات الصناعة والتوقعات حتى عام 2028
تحليل السوق والرؤى: سوق النقل الجيني في أوروبا
من المتوقع أن يحقق سوق النقل الجيني في أوروبا نموًا في السوق في الفترة المتوقعة من 2021 إلى 2028. تحلل شركة Data Bridge Market Research أن السوق ينمو بمعدل نمو سنوي مركب قدره 8.96٪ في الفترة المتوقعة من 2021 إلى 2028 ومن المتوقع أن يصل إلى 411.24 مليون دولار أمريكي بحلول عام 2028.
تعد عمليات النقل الجيني واسعة النطاق المستخدمة في الأبحاث السريرية واستخدام المستحضرات الصيدلانية الحيوية في إنتاج البروتينات من المحركات الرئيسية التي دفعت الطلب على السوق في الفترة المتوقعة.
تتضمن عملية التحويل ميزات مثل الحاجة المتزايدة إلى خيارات علاجية أفضل ستؤثر على إطلاق منتج جديد من قبل الشركات المصنعة في السوق مما يعزز الطلب عليه بالإضافة إلى زيادة الاستثمار في البحث والتطوير مما يؤدي إلى نمو السوق. تجري حاليًا دراسات بحثية مختلفة ومن المتوقع أن تخلق ميزة تنافسية للشركات المصنعة لتطوير منتجات تحويل جديدة ومبتكرة ومن المتوقع أن توفر فرصًا أخرى مختلفة في سوق التحويل. ومع ذلك، من المتوقع أن يؤدي تلف الخلايا الناجم عن طرق التحويل والافتقار إلى مختبر مستوى الأمان للتحويل المرتبط بالفيروس إلى كبح نمو السوق في فترة التنبؤ.
يقدم تقرير سوق التحويل الجيني تفاصيل عن حصة السوق والتطورات الجديدة وتحليل خط أنابيب المنتجات وتأثير اللاعبين المحليين والمحليين في السوق وتحليل الفرص من حيث جيوب الإيرادات الناشئة والتغييرات في لوائح السوق وموافقات المنتجات والقرارات الاستراتيجية وإطلاق المنتجات والتوسعات الجغرافية والابتكارات التكنولوجية في السوق. لفهم التحليل وسيناريو السوق، اتصل بنا للحصول على موجز محلل، وسيساعدك فريقنا في إنشاء حل لتأثير الإيرادات لتحقيق هدفك المنشود.
نطاق سوق النقل الجيني وحجم السوق في أوروبا
يتم تقسيم سوق التحويل الجيني إلى عشرة قطاعات بارزة تعتمد على النوع والطرق وطرق التحويل الجيني باستخدام CRISPR والمنتجات والكائنات الحية وأنواع الجزيئات والتطبيق والمرحلة والمستخدم النهائي وقناة التوزيع. يساعدك النمو بين القطاعات على تحليل جيوب النمو والاستراتيجيات المتخصصة للتعامل مع السوق وتحديد مجالات التطبيق الأساسية لديك والاختلاف في الأسواق المستهدفة.
- على أساس النوع، يتم تقسيم سوق التحويل الجيني إلى التحويل الجيني المؤقت والتحويل الجيني المستقر. في عام 2021، يهيمن التحويل الجيني المؤقت على السوق لأنه يستخدم لإنتاج عدد كبير من نسخ الخلايا المحولة للحصول على مستوى عالٍ من التعبير البروتيني في فترة زمنية أقل من خلال الجينات المستنسخة.
- على أساس الأساليب، يتم تقسيم سوق التحويل الجيني إلى أساليب غير فيروسية وأساليب فيروسية. في عام 2021، تهيمن الأساليب غير الفيروسية لأنها متوافقة مع معظم أنواع الخلايا؛ علاوة على ذلك، فإن الكواشف المستخدمة في التحويل الجيني غير الفيروسي باهظة الثمن ومتوفرة بسهولة.
- على أساس طرق نقل الجينات باستخدام تقنية CRISPR، يتم تقسيم سوق نقل الجينات إلى طرق غير فيروسية وطرق فيروسية. في عام 2021، تهيمن الطرق غير الفيروسية على نقل الجينات باستخدام تقنية CRISPR (تكرارات قصيرة منتظمة متباعدة) لأنها توفر كفاءة نقل جينية عالية ونقل مطلق لتسلسلات CRISPR.
- على أساس المنتجات، يتم تقسيم سوق التحويل الجيني إلى كواشف ومجموعات وأدوات وبرامج . في عام 2021، تهيمن الكواشف والمجموعات على سوق التحويل الجيني في أوروبا حيث تُستخدم لتعزيز فعالية عملية التحويل الجيني في التجارب الجينية المختلفة بين أنواع أخرى من عمليات الإنتاج مثل علم الأحياء الاصطناعي.
- على أساس الكائن الحي، يتم تقسيم سوق النقل الجيني إلى خلايا الثدييات والنباتات والفطريات والفيروسات والبكتيريا. في عام 2021، تهيمن خلايا الثدييات على سوق النقل الجيني في أوروبا حيث أن النقل الجيني لخلايا الثدييات هو تقنية تُستخدم عادةً للتعبير عن جزيئات الأحماض النووية الخارجية في سلالة خلية مضيفة أثناء إنتاج البروتينات واليوروكيناز وFSH وغيرها.
- على أساس أنواع الجزيئات، يتم تقسيم سوق التحويل إلى DNA البلازميدي، وRNA المتداخل الصغير (siRNA)، والبروتينات، ونوكليوتيدات DNA، ومجمعات الريبونوكليوبروتين (RNPs) وغيرها. في عام 2021، يهيمن DNA البلازميدي على سوق التحويل في أوروبا حيث يحتوي DNA البلازميدي على الجينات المؤتلفة وعناصر تنظيمية أخرى وهي المصدر الأساسي للتعبير عن البروتين.
- على أساس التطبيق، يتم تقسيم سوق النقل الجيني إلى تطبيق في المختبر، وتطبيق في الجسم الحي، والإنتاج البيولوجي، وغير ذلك. في عام 2021، يهيمن تطبيق في المختبر على سوق النقل الجيني في أوروبا لأنه يوفر توصيل جزيئات الأحماض النووية إلى الخلايا المزروعة لأغراض البحث وكذلك للإنتاج التجاري للجزيئات.
- على أساس المرحلة، يتم تقسيم سوق التحويل الجيني إلى مرحلة بحثية ومرحلة ما قبل السريرية ومرحلة سريرية ومرحلة تجارية . في عام 2021، يهيمن البحث على السوق بسبب الطلب المتزايد على التعبير الجيني عبر التطبيقات البيولوجية المختلفة.
- على أساس المستخدم النهائي، يتم تقسيم سوق التحويل الجيني إلى شركات الأدوية الحيوية، ومنظمات الأبحاث التعاقدية (CROs)، ومنظمات التصنيع التعاقدي/منظمات التطوير والتصنيع التعاقدية (CMOs/CDMOs)، والأوساط الأكاديمية، والمستشفيات، والمختبرات السريرية وغيرها. في عام 2021، استحوذت شركات الأدوية الحيوية على أكبر حصة في السوق لأن صناعة الأدوية الحيوية تستخدم عملية التحويل الجيني لإنتاج البروتين التجاري بتكلفة فعالة.
- على أساس قناة التوزيع، يتم تقسيم سوق التحويل الجيني إلى عطاءات مباشرة ومبيعات التجزئة وغيرها. في عام 2021، تهيمن العطاءات المباشرة على السوق حيث تفضل معظم صناعات الأدوية الحيوية العطاءات المباشرة للحصول على كاشف التحويل الجيني والمجموعات والأدوات الأكثر موثوقية وفعالية من حيث التكلفة.
تحليل سوق التحويل الجيني على مستوى الدولة
يتم تحليل سوق النقل الجيني وتوفير معلومات حجم السوق على أساس النوع والأساليب وطرق النقل الجيني CRISPR والمنتجات والكائن الحي وأنواع الجزيئات والتطبيق والمرحلة والمستخدم النهائي وقناة التوزيع.
الدول التي يغطيها تقرير سوق النقل الجيني هي ألمانيا وفرنسا وإيطاليا والمملكة المتحدة وإسبانيا وسويسرا وروسيا وهولندا وبلجيكا وتركيا وبقية أوروبا.
من المتوقع أن تنمو ألمانيا في أوروبا بمعدل نمو واعد في الفترة المتوقعة من 2021 إلى 2028 مع ارتفاع الطلب على إنتاج البروتين العلاجي وارتفاع مستوى الاستثمارات. تهيمن ألمانيا على المنطقة الأوروبية بسبب التركيز الكبير على التكنولوجيا الوراثية للأغراض التجارية والسريرية.
كما يوفر قسم الدولة في التقرير عوامل التأثير الفردية على السوق والتغييرات في التنظيم في السوق محليًا والتي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. تعد نقاط البيانات مثل المبيعات الجديدة ومبيعات الاستبدال والتركيبة السكانية للدولة والقوانين التنظيمية ورسوم الاستيراد والتصدير من بين المؤشرات الرئيسية المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود وتوافر العلامات التجارية الأوروبية والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية وتأثير قنوات المبيعات أثناء تقديم تحليل توقعات لبيانات الدولة.
إن عمليات النقل واسعة النطاق المستخدمة في البحث السريري واستكشاف الأسواق الناشئة تعمل على تعزيز نمو سوق النقل
يوفر لك سوق التحويل الجيني أيضًا تحليلًا تفصيليًا للسوق لكل دولة من حيث نمو صناعة التحويل الجيني مع مبيعات أدوية التحويل الجيني وتأثير التقدم في تكنولوجيا التحويل الجيني والتغييرات في السيناريوهات التنظيمية مع دعمها لسوق التحويل الجيني. تتوفر البيانات للفترة التاريخية من 2011 إلى 2019.
تحليل المشهد التنافسي وحصة سوق النقل الجيني
يوفر المشهد التنافسي لسوق التحويل الجيني تفاصيل حسب المنافس. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، ومواقع الإنتاج والمرافق، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وخطوط أنابيب تجارب المنتجات، وموافقات المنتج، وبراءات الاختراع، وعرض المنتج وتنفسه، وهيمنة التطبيق، ومنحنى شريان الحياة التكنولوجي. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركة فيما يتعلق بسوق التحويل الجيني.
الشركات الرئيسية التي تتعامل في مجال النقل الجيني هي Mirus Bio LLC.، وPromega Corporation، وPolyplus Transfection، وBio-Rad Laboratories, Inc.، وMerck KGaA، وLonza، وMaxCyte, Inc.، وPerkinElmer chemagen Technologie GmbH (شركة تابعة لشركة PerkinElmer Inc.)، وCytiva، وR&D Systems, Inc.، وTakara Bio Inc.، وQIAGEN، وOriGene Technologies, Inc.، وApplied Biological Materials Inc. (abm)، وBeckman Coulter, Inc. (شركة تابعة لشركة Danaher)، وAmyris، وCodexis، وAutolus، وSignaGen Laboratories، وBioscience، وغيرها.
كما تقوم الشركات في جميع أنحاء العالم أيضًا بمبادرة إطلاق العديد من المنتجات والاتفاقيات والتي تعمل أيضًا على تسريع سوق النقل الجيني.
- في أبريل 2019، أطلقت شركة Polyplus Transfection منتج FectoVIR-AAV، وهو كاشف تحويل يستخدم للحصول على عوائد عالية من عيار الفيروس المرتبط بالغدة الدرقية. وقد عزز إطلاق هذا المنتج محفظة منتجات الشركة وسمح لها بتوسيع شبكتها في سوق التحويل.
يعمل التعاون وإطلاق المنتج وتوسيع الأعمال والجوائز والتقدير والمشاريع المشتركة والاستراتيجيات الأخرى من قبل اللاعب في السوق على تعزيز سوق الشركة في سوق النقل الجيني مما يوفر أيضًا فائدة للمنظمة لتحسين عرضها لسوق النقل الجيني.
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE TRANSFECTION MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TRANSIENT TRANSFECTION OF TRANSFECTION LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 TOTAL ADDRESSABLE MARKET
4.1.1 BY METHOD/MODALITY
4.1.2 BY END USER
4.1.3 BY APPLICATION
4.1.4 BY STAGE
4.2 EARLY AND LATE STAGE CELL LINE DEVELOPMENT FOR BIOPHARMA AND VIRAL VECTOR PRODUCTION FOR GENE THERAPY
4.2.1 THE LIST OF APPROVED ANTIBODIES PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS AND LIST OF SELECTABLE MARKERS USED IN MAMMALIAN EXPRESSION VECTORS
5 REGULATORY FRAMEWORK
5.1 EUROPEAN UNION REGULATORY SCENARIO
5.2 U.S. REGULATORY SCENARIO
5.3 JAPAN REGULATORY SCENARIO
5.4 CHINA REGULATORY SCENARIO
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES
6.1.2 DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS
6.1.3 GROWING DEMAND OF CHIMERIC GENES
6.1.4 LARGE-SCALE TRANSFECTIONS USED IN CLINICAL RESEARCH
6.1.5 UTILIZATION OF BIOPHARMACEUTICALS IN THE PRODUCTION OF PROTEINS
6.2 RESTRAINTS
6.2.1 HIGH COST OF TRANSFECTION PRODUCTS
6.2.2 SELECTIVE EFFECTIVENESS OF TRANSFECTION REAGENTS
6.2.3 CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE
6.3 OPPORTUNITIES
6.3.1 EXPLORATION OF EMERGING MARKET
6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.3 INCREASING GOVERNMENT SUPPORT
6.3.4 SURGING LEVEL OF INVESTMENT
6.4 CHALLENGES
6.4.1 LONG APPROVAL PROCEDURE
6.4.2 LACK OF SAFETY LEVEL LAB FOR VIRUS ASSOCIATED TRANSFECTION
6.4.3 LACK OF TRAINED PROFESSIONALS
7 COVID-19 IMPACT OF EUROPE TRANSFECTION MARKET IN HEALTHCARE INDUSTRY
7.1 OVERVIEW
7.2 IMPACT ON THE PRICE
7.3 IMPACT ON DEMAND
7.4 IMPACT ON SUPPLY CHAIN
7.5 STRATEGIC INITIATIVE BY MANUFACTURERS
7.6 CONCLUSION
8 EUROPE TRANSFECTION MARKET, BY TYPE
8.1 OVERVIEW
8.2 TRANSIENT TRANSFECTION
8.2.1 BY STAGE
8.2.1.1 RESEARCH
8.2.1.2 PRECLINICAL
8.2.1.3 CLINICAL PHASES
8.2.1.4 COMMERCIAL
8.2.2 BY PRODUCT
8.2.2.1 REAGENT & KITS
8.2.2.2 INSTRUMENTS
8.2.2.3 SOFTWARE
8.3 STABLE TRANSECTION
8.3.1 BY STAGE
8.3.1.1 RESEARCH
8.3.1.2 PRECLINICAL
8.3.1.3 CLINICAL PHASES
8.3.1.4 COMMERCIAL
8.3.2 BY PRODUCT
8.3.2.1 REAGENT & KITS
8.3.2.2 INSTRUMENTS
8.3.2.3 SOFTWARE
9 EUROPE TRANSFECTION MARKET, BY METHODS
9.1 2.1 OVERVIEW
9.2 NON- VIRAL METHODS
9.2.1 CHEMICAL
9.2.1.1 Lipofection Method
9.2.1.2 Calcium Phosphate Precipitation Method
9.2.1.3 Polyethylenimine (PEI)–DNA Condensation Method
9.2.1.4 Others
9.2.2 PHYSICAL
9.2.2.1 Electroporation
9.2.2.2 Direct Microinjection
9.2.2.3 Biolistic Particle Delivery/ Particle Bombardment
9.2.2.4 Magnetofection
9.2.2.5 Sonoporation
9.2.2.6 Others
9.3 VIRAL METHODS
9.3.1 RETROVIRUS TRANSFECTION
9.3.2 ADENOVIRUS TRANSFECTION
9.3.3 LENTIVIRUS TRANSFECTION
9.3.4 OTHERS
10 EUROPE TRANSFECTION MARKET, BY METHODS
10.1 OVERVIEW
10.2 NON- VIRAL METHODS
10.2.1 CHEMICAL
10.2.1.1 Lipofection Method
10.2.1.2 Calcium Phosphate Precipitation Method
10.2.1.3 Polyethylenimine (PEI)–DNA Condensation Method
10.2.1.4 Others
10.2.2 PHYSICAL
10.2.2.1 Electroporation
10.2.2.2 Direct Microinjection
10.2.2.3 Biolistic Particle Delivery/ Particle Bombardment
10.2.2.4 Magnetofection
10.2.2.5 Sonoporation
10.2.2.6 Others
10.3 VIRAL METHODS
10.3.1 RETROVIRUS TRANSFECTION
10.3.2 ADENOVIRUS TRANSFECTION
10.3.3 LENTIVIRUS TRANSFECTION
10.3.4 OTHERS
11 EUROPE TRANSFECTION MARKET, BY PRODUCTS
11.1 OVERVIEW
11.2 REAGENTS & KITS
11.2.1 CATIONIC LIPIDS
11.2.1.1 Liposomal Reagents
11.2.1.1.1 L-Dioleoyl Phosphatidylethanolamine (DOPE)
11.2.1.1.2 DOTAP [1,2-Dioleoyloxy-3-Trimethylammonium Propane]
11.2.1.1.3 DOTMA [N-[1(2,3-Dioleoyloxy)Propyl]-N,N,N-Trimethylammonium Chloride]
11.2.1.1.4 Others
11.2.1.2 Non-Liposomal Reagents
11.2.1.2.1 DNA Transfection Reagent
11.2.1.2.2 siRNA Transfection Reagent
11.2.1.2.3 Others
11.2.2 CATIONIC POLYMER
11.2.2.1 DEAE-Dextran
11.2.2.2 Polybrene
11.2.2.3 Polyethyleneimine
11.2.2.4 Dendrimers
11.2.2.5 Others
11.2.3 NANOPARTICLES
11.2.3.1 Systemic Intravenous Injection
11.2.3.2 Direct Intratumoral Injection
11.2.4 KITS
11.2.4.1 Transporter Transfection Reagent
11.2.4.2 GMP Transfection Reagent
11.2.4.3 Neon Electroporation
11.2.4.4 Cellfectin Ii Transfection Reagent
11.2.4.5 DMRIE-C Transfection Reagent
11.2.4.6 Lipofectamine Transfection Reagent
11.2.4.7 Lipofectin Transfection Reagent
11.2.4.8 Oligofectamine Transfection Reagent
11.2.4.9 Optifect Transfection Reagent
11.2.4.10 Cell Specific Transfection Reagent
11.2.4.11 Gene Gun Kit
11.2.4.12 Plasmid Transfection Reagent
11.2.4.13 Others
11.2.5 CUVETTE CHAMBER
11.2.6 OTHERS
11.3 INSTRUMENT
11.3.1 ELECTROPORATION SYSTEM
11.3.1.1 Neon Transfection System
11.3.1.2 Others
11.3.2 ELECTRO-CELL FUSION GENERATOR
11.3.3 ELECTRO-KINETIC TRANSFECTION SYSTEM
11.3.4 HEPTA SYSTEM
11.3.5 TUBING PREP STATION
11.3.6 RT-PCR
11.3.7 GUN SYSTEM
11.3.8 MICROPLATE READER
11.3.9 SONOPORATION SYSTEM
11.3.10 MICROSCOPES
11.3.11 OTHERS
12 EUROPE TRANSFECTION MARKET, BY ORGANISM
12.1 OVERVIEW
12.2 MAMMALIAN CELLS
12.3 PLANTS
12.4 FUNGI
12.5 VIRUS
12.6 BACTERIA
13 EUROPE TRANSFECTION MARKET, BY TYPES OF MOLECULE
13.1 OVERVIEW
13.2 PLASMID DNA
13.3 SMALL INTERFERING RNA (SIRNA)
13.4 PROTEINS
13.5 DNA OLIGONUCLEOTIDES
13.6 RIBONUCLEOPROTEIN COMPLEXES (RNPS)
13.7 OTHERS
14 EUROPE TRANSFECTION MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 BY TYPE
14.2.1 IN VITRO APPLICATION
14.2.1.1 Gene Expression
14.2.1.2 RNA Interference
14.2.2 IN VIVO APPLICATION
14.2.2.1 Gene Therapy
14.2.2.2 Cellular-Based Therapy
14.2.3 BIOPRODUCTION
14.2.3.1 Antibody/Protein Production
14.2.3.2 Virus Production
14.2.4 OTHERS
14.3 BY INDUSTRY
14.3.1 SYNTHETIC BIOLOGY
14.3.1.1 Biopharma
14.3.1.2 Monoclonal Antibodies (mAbs)
14.3.1.3 Recombinant Proteins
14.3.1.4 Biofuels
14.3.1.5 Cell Line Development
14.3.1.6 Flavors & Fragrances
14.3.1.7 Enzyme Engineering & Production
14.3.1.8 Specialty Chemicals
14.3.2 AGRICULTURE
14.3.3 OTHERS
15 EUROPE TRANSFECTION MARKET, BY STAGES
15.1 OVERVIEW
15.2 RESEARCH
15.3 PRECLINICAL
15.4 CLINICAL PHASES
15.5 COMMERCIAL
16 EUROPE TRANSFECTION MARKET, BY END USER
16.1 OVERVIEW
16.2 BIOPHARMA
16.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
16.4 CONTRACT MANUFACTURING ORGANIZATION/ CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CMOS/CDMOS)
16.5 ACADEMIA
16.6 HOSPITALS
16.7 CLINICAL LABS
16.8 OTHERS
17 EUROPE TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDERS
17.3 RETAIL SALES
17.4 OTHERS
18 EUROPE TRASNFECTION MARKET, BY GEOGRAPHY
18.1 EUROPE
18.1.1 GERMANY
18.1.2 FRANCE
18.1.3 ITALY
18.1.4 U.K.
18.1.5 SPAIN
18.1.6 SWITZERLAND
18.1.7 RUSSIA
18.1.8 NETHERLANDS
18.1.9 BELGIUM
18.1.10 TURKEY
18.1.11 REST OF EUROPE
19 EUROPE TRANSFECTION MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: EUROPE
20 SWOT ANALYSIS
21 COMPANY PROFILE
21.1 THERMOFISHER SCIENTIFIC INC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 ROCHE MOLECULAR SYSTEMS, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMAPYN SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 QIAGEN
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.4 PROMEGA CORPORATION
21.4.1 COMPANY SNAPSHOT
21.4.2 COMPANY SHARE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENTS
21.5 TAKARA BIO INC.
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 BIO-RAD LABORATORIES, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANANLYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 LONZA
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANANLYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 CYTIVA
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENTS
21.9 ALTOGEN BIOSYSTEMS
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENTS
21.1 AMYRIS
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENTS
21.11 APPLIED BIOLOGICAL MATERIALS INC. (ABM)
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENT
21.12 AUTOLUS
21.12.1 COMPANY SNAPSHOT
21.12.2 PRODUCT PORTFOLIO
21.12.3 RECENT DEVELOPMENTS
21.13 AVANTI POLAR LIPIDS (A SUBSIDIARY OF CRODA INTERNATIONAL PLC)
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENTS
21.15 CODEXIS
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 CONAGEN, INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 PRODUCT PORTFOLIO
21.16.3 RECENT DEVELOPMENTS
21.17 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANANLYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENT
21.18 GENLANTIS INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 PRODUCT PORTFOLIO
21.18.3 RECENT DEVELOPMENTS
21.19 GENO TECHNOLOGY INC., USA
21.19.1 COMPANY SNAPSHOT
21.19.2 PRODUCT PORTFOLIO
21.19.3 RECENT DEVELOPMENTS
21.2 GINKGO BIOWORKS
21.20.1 COMPANY SNAPSHOT
21.20.2 PRODUCT PORTFOLIO
21.20.3 RECENT DEVELOPMENTS
21.21 IMPOSSIBLE FOODS INC.
21.21.1 COMPANY SNAPSHOT
21.21.2 PRODUCT PORTFOLIO
21.21.3 RECENT DEVELOPMENTS
21.22 MAXCYTE, INC.
21.22.1 COMPANY SNAPSHOT
21.22.2 REVENUE ANALYSIS
21.22.3 PRODUCT PORTFOLIO
21.22.4 RECENT DEVELOPMENTS
21.23 MERCK KGAA
21.23.1 COMPANY SNAPSHOT
21.23.2 REVENUE ANALYSIS
21.23.3 PRODUCT PORTFOLIO
21.23.4 RECENT DEVELOPMENTS
21.24 MIRUS BIO LLC.
21.24.1 COMPANY SNAPSHOT
21.24.2 PRODUCT PORTFOLIO
21.24.3 RECENT DEVELOPMENTS
21.25 ORIGENE TECHNOLOGIES, INC.
21.25.1 COMPANY SNAPSHOT
21.25.2 PRODUCT PORTFOLIO
21.25.3 RECENT DEVELOPMENTS
21.26 PERKINELMER CHEMAGEN TECHNOLOGIE GMBH (A SUBSIDIARY OF PERKINELMER INC.)
21.26.1 COMPANY SNAPSHOT
21.26.2 REVENUE ANANLYSIS
21.26.3 PRODUCT PORTFOLIO
21.26.4 RECENT DEVELOPMENTS
21.27 POLYPLUS TRANSFECTION
21.27.1 COMPANY SNAPSHOT
21.27.2 PRODUCT PORTFOLIO
21.27.3 RECENT DEVELOPMENTS
21.28 POSEIDA THERAPEUTICS, INC.
21.28.1 COMPANY SNAPSHOT
21.28.2 PRODUCT PORTFOLIO
21.28.3 RECENT DEVELOPMENTS
21.29 R&D SYSTEMS, INC.
21.29.1 COMPANY SNAPSHOT
21.29.2 PRODUCT PORTFOLIO
21.29.3 RECENT DEVELOPMENT
21.3 SBS GENETECH
21.30.1 COMPANY SNAPSHOT
21.30.2 PRODUCT PORTFOLIO
21.30.3 RECENT DEVELOPMENTS
21.31 SIGNAGEN LABORATORIES
21.31.1 COMPANY SNAPSHOT
21.31.2 PRODUCT PORTFOLIO
21.31.3 RECENT DEVELOPMENTS
21.32 TWIST BIOSCIENCE
21.32.1 COMPANY SNAPSHOT
21.32.2 REVENUE ANALYSIS
21.32.3 PRODUCT PORTFOLIO
21.32.4 RECENT DEVELOPMENTS
21.33 VERVE THERAPEUTICS, INC.
21.33.1 COMPANY SNAPSHOT
21.33.2 PRODUCT PORTFOLIO
21.33.3 RECENT DEVELOPMENTS
21.34 ZYMERGEN INC.
21.34.1 COMPANY SNAPSHOT
21.34.2 PRODUCT PORTFOLIO
21.34.3 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 LIST OF APPROVED ANTIBODIES PRODUCED IN CHO CELLS
TABLE 2 EU DIRECTIVES AND REGULATIONS RELATED TO CLINICAL TRIALS INVOLVING GTMPS
TABLE 3 GOVERNMENT ENTITIES THAT ARE IN CHARGE OF TYPE 2 USES
TABLE 4 EUROPE TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 5 EUROPE TRANSIENT TRANSFECTION IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 6 EUROPE TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 7 EUROPE TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 8 EUROPE STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 EUROPE STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 EUROPE TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 11 EUROPE NON- VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 12 EUROPE NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 13 EUROPE CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 14 EUROPE PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 15 EUROPE VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 16 EUROPE VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 17 EUROPE CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 18 EUROPE NON- VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 19 EUROPE NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 20 EUROPE CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 21 EUROPE PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 22 EUROPE VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 23 EUROPE VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 24 EUROPE REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 25 EUROPE REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 26 EUROPE CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 27 EUROPE LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 28 EUROPE NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 29 EUROPE CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 30 EUROPE NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 31 EUROPE KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 32 EUROPE INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 33 EUROPE INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 34 EUROPE ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 35 EUROPE SOFTWARE BY INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 37 EUROPE MAMMALIAN CELLS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 EUROPE PLANTS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 EUROPE FUNGI IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 EUROPE VIRUS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 EUROPE BACTERIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 EUROPE TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 43 EUROPE PLASMID DNA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 EUROPE BACTERIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 EUROPE PROTEINS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 EUROPE DNA OLIGONUCLEOTIDES IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 EUROPE RIBONUCLEOPROTEIN COMPLEXES (RNPS) IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 EUROPE BACTERIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 EUROPETRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 50 EUROPE IN VITRO APPLICATION IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 52 EUROPE IN VIVO APPLICATION IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 54 EUROPE BIOPRODUCTION IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 56 EUROPE OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 57 EUROPE TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 58 EUROPE SYNTHETIC BIOLOGY IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 60 EUROPE AGRICULTURE IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 61 EUROPE OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 63 EUROPE RESEARCH IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 64 EUROPE PRE-CLINICAL IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 65 EUROPE CLINICAL PHASES IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 66 EUROPE COMMERCIAL IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 67 NORTH AMERICA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 68 EUROPE BIOPHARMA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 69 EUROPE CONTRACT RESEARCH ORGANIZATIONS (CROS) IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 70 EUROPE CONTRACT MANUFACTURING ORGANIZATION/ CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CMOS/CDMOS) IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 71 EUROPE ACADEMIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 72 EUROPE HOSPITALS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 73 EUROPE CLINICAL LABS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 74 EUROPE OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 75 NORTH AMERICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 76 EUROPE DIRECT TENDER IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 77 EUROPE RETAIL SALES IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 78 EUROPE OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 1 EUROPE TRANSFECTION MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 2 EUROPE TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 3 EUROPE TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 4 EUROPE TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 EUROPE STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 EUROPE STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 7 EUROPE TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 8 EUROPE NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 9 EUROPE CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 10 EUROPE PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 11 EUROPE VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 12 EUROPE CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 13 EUROPE NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 14 EUROPE CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 15 EUROPE PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 16 EUROPE VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 17 EUROPE TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 18 EUROPE REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 19 EUROPE CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 20 EUROPE LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 21 EUROPE NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 22 EUROPE CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 23 EUROPE KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 24 EUROPE NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 25 EUROPE INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 26 EUROPE INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 27 EUROPE ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 28 EUROPE TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 29 EUROPE TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 30 EUROPE AMERICATRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 31 EUROPE IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 32 EUROPE IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 33 EUROPE BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 34 EUROPE TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 35 EUROPE SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 36 EUROPE TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 37 EUROPE TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 EUROPE TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 GERMANY TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 40 GERMANY TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 41 GERMANY TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 42 GERMANY STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 43 GERMANY STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 44 GERMANY TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 45 GERMANY NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 46 GERMANY CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 47 GERMANY PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 48 GERMANY VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 49 GERMANY CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 50 GERMANY NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 51 GERMANY CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 52 GERMANY PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 53 GERMANY VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 54 GERMANY TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 55 GERMANY REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 56 GERMANY CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 57 GERMANY LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 58 GERMANY NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 59 GERMANY CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 60 GERMANY KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 61 GERMANY NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 62 GERMANY INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 63 GERMANY INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 64 GERMANY ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 65 GERMANY TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 66 GERMANY TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 67 GERMANY TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 68 GERMANY IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 69 GERMANY IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 70 GERMANY BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 71 GERMANY TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 72 GERMANY SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 GERMANY TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 74 GERMANY TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 75 GERMANY TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 76 FRANCE TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 77 FRANCE TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 FRANCE TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 FRANCE STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 FRANCE STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 FRANCE TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 82 FRANCE NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 83 FRANCE CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 84 FRANCE PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 85 FRANCE VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 86 FRANCE CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 87 FRANCE NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 88 FRANCE CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 89 FRANCE PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 90 FRANCE VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 91 FRANCE TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 92 FRANCE REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 93 FRANCE CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 94 FRANCE LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 95 FRANCE NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 96 FRANCE CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 97 FRANCE KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 98 FRANCE NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 99 FRANCE INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 100 FRANCE INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 101 FRANCE ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 102 FRANCE TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 103 FRANCE TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 104 FRANCE TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 105 FRANCE IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 106 FRANCE IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 107 FRANCE BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 108 FRANCE TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 109 CANADA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 110 FRANCE TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 111 FRANCE TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 112 FRANCE TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 113 ITALY TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 114 ITALY TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 ITALY TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 ITALY STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 117 ITALY STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 118 ITALY TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 119 ITALY NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 120 ITALY CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 121 ITALY PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 122 ITALY VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 123 ITALY CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 124 ITALY NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 125 ITALY CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 126 ITALY PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 127 ITALY VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 128 ITALY TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 129 ITALY REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 130 ITALY CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 131 ITALY LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 132 ITALY NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 133 ITALY CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 134 ITALY KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 135 ITALY NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 136 ITALY INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 137 ITALY INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 138 ITALY ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 139 ITALY TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 140 ITALY TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 141 ITALY TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 142 ITALY IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 143 ITALY IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 144 ITALY BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 145 ITALY TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 146 ITALY SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 147 ITALY TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 148 ITALY TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 149 ITALY TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 150 UK TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 151 UK TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 152 UK TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 153 UK STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 154 UK STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 UK TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 156 UK NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 157 UK CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 158 UK PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 159 UK VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 160 UK CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 161 UK NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 162 UK CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 163 UK PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 164 UK VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 165 UK TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 166 UK REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 167 UK CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 168 UK LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 169 UK NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 170 UK CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 171 UK KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 172 UK NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 173 UK INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 174 UK INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 175 UK ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 176 UK TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 177 UK TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 178 UKTRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 179 UK IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 180 UK IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 181 UK BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 182 UK TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 183 UK SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 184 UK TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 185 UK TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 186 UK TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 187 SPAIN TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 188 SPAIN TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 189 SPAIN TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 190 SPAIN STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 SPAIN STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 192 SPAIN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 193 SPAIN NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 194 SPAIN CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 195 SPAIN PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 196 SPAIN VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 197 SPAIN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 198 SPAIN NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 199 SPAIN CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 200 SPAIN PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 201 SPAIN VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 202 SPAIN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 203 SPAIN REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 204 SPAIN CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 205 SPAIN LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 206 SPAIN NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 207 SPAIN CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 208 SPAIN KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 209 SPAIN NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 210 SPAIN INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 211 SPAIN INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 212 SPAIN ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 213 SPAIN TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 214 SPAIN TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 215 SPAIN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 216 SPAIN IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 217 SPAIN IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 218 SPAIN BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 219 SPAIN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 220 SPAIN SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 221 SPAIN TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 222 SPAIN TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 223 SPAIN TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 224 SWITZERLAND TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 225 SWITZERLAND TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 226 SWITZERLAND TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 227 SWITZERLAND STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 228 SWITZERLAND STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 229 SWITZERLAND TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 230 SWITZERLAND NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 231 SWITZERLAND CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 232 SWITZERLAND PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 233 SWITZERLAND VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 234 SWITZERLAND CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 235 SWITZERLAND NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 236 SWITZERLAND CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 237 SWITZERLAND PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 238 SWITZERLAND VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 239 SWITZERLAND TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 240 SWITZERLAND REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 241 SWITZERLAND CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 242 SWITZERLAND LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 243 SWITZERLAND NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 244 SWITZERLAND CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 245 SWITZERLAND KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 246 SWITZERLAND NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 247 SWITZERLAND INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 248 SWITZERLAND INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 249 SWITZERLAND ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 250 SWITZERLAND TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 251 SWITZERLAND TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 252 SWITZERLAND TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 253 SWITZERLAND IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 254 SWITZERLAND IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 255 SWITZERLAND BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 256 SWITZERLAND TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 257 SWITZERLAND SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 258 SWITZERLAND TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 259 SWITZERLAND TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 260 SWITZERLAND TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 261 RUSSIA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 262 RUSSIA TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 263 RUSSIA TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 264 RUSSIA STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 265 RUSSIA STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 266 RUSSIA TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 267 RUSSIA NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 268 RUSSIA CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 269 RUSSIA PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 270 RUSSIA VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 271 RUSSIA CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 272 RUSSIA NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 273 RUSSIA CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 274 RUSSIA PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 275 RUSSIA VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 276 RUSSIA TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 277 RUSSIA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 278 RUSSIA CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 279 RUSSIA LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 280 RUSSIA NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 281 RUSSIA CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 282 RUSSIA KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 283 RUSSIA NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 284 RUSSIA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 285 RUSSIA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 286 RUSSIA ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 287 RUSSIA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 288 RUSSIA TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 289 RUSSIATRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 290 RUSSIA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 291 RUSSIA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 292 RUSSIA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 293 RUSSIA TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 294 RUSSIA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 295 RUSSIA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 296 RUSSIA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 297 RUSSIA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 298 NETHERLANDS TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 299 NETHERLANDS TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 300 NETHERLANDS TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 301 NETHERLANDS STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 302 NETHERLANDS STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 303 NETHERLANDS TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 304 NETHERLANDS NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 305 NETHERLANDS CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 306 NETHERLANDS PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 307 NETHERLANDS VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 308 NETHERLANDS CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 309 NETHERLANDS NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 310 NETHERLANDS CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 311 NETHERLANDS PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 312 NETHERLANDS VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 313 NETHERLANDS TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 314 NETHERLANDS REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 315 NETHERLANDS CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 316 NETHERLANDS LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 317 NETHERLANDS NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 318 NETHERLANDS CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 319 NETHERLANDS KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 320 NETHERLANDS NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 321 NETHERLANDS INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 322 NETHERLANDS INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 323 NETHERLANDS ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 324 NETHERLANDS TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 325 NETHERLANDS TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 326 NETHERLANDSTRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 327 NETHERLANDS IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 328 NETHERLANDS IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 329 NETHERLANDS BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 330 NETHERLANDS TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 331 NETHERLANDS SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 332 NETHERLANDS TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 333 NETHERLANDS TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 334 NETHERLANDS TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 335 BELGIUM TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 336 BELGIUM TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 337 BELGIUM TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 338 BELGIUM STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 339 BELGIUM STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 340 BELGIUM TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 341 BELGIUM NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 342 BELGIUM CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 343 BELGIUM PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 344 BELGIUM VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 345 BELGIUM CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 346 BELGIUM NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 347 BELGIUM CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 348 BELGIUM PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 349 BELGIUM VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 350 BELGIUM TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 351 BELGIUM REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 352 BELGIUM CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 353 BELGIUM LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 354 BELGIUM NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 355 BELGIUM CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 356 BELGIUM KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 357 BELGIUM NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 358 BELGIUM INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 359 BELGIUM INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 360 BELGIUM ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 361 BELGIUM TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 362 BELGIUM TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 363 BELGIUM TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 364 BELGIUM IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 365 BELGIUM IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 366 BELGIUM BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 367 BELGIUM TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 368 BELGIUM SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 369 BELGIUM TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 370 BELGIUM TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 371 BELGIUM TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 372 TURKEY TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 373 TURKEY TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 374 TURKEY TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 375 TURKEY STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 376 TURKEY STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 377 TURKEY TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 378 TURKEY NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 379 TURKEY CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 380 TURKEY PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 381 TURKEY VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 382 TURKEY CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 383 TURKEY NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 384 TURKEY CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 385 TURKEY PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 386 TURKEY VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 387 TURKEY TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 388 TURKEY REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 389 TURKEY CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 390 TURKEY LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 391 TURKEY NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 392 TURKEY CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 393 TURKEY KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 394 TURKEY NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 395 TURKEY INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 396 TURKEY INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 397 TURKEY ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 398 TURKEY TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 399 TURKEY TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 400 TURKEY TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 401 TURKEY IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 402 TURKEY IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 403 TURKEY BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 404 TURKEY TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 405 TURKEY SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 406 TURKEY TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 407 TURKEY TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 408 TURKEY TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 409 REST OF EUROPE TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 EUROPE TRANSFECTION MARKET: SEGMENTATION
FIGURE 2 EUROPE TRANSFECTION MARKET : DATA TRIANGULATION
FIGURE 3 EUROPE TRANSFECTION MARKET: DROC ANALYSIS
FIGURE 4 EUROPE TRANSFECTION MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE TRANSFECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE TRANSFECTION MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE TRANSFECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE TRANSFECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE TRANSFECTION MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 10 EUROPE TRANSFECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE TRANSFECTION MARKET: SEGMENTATION
FIGURE 12 INCREASING OCCURENCE OF CHRONIC DISEASES AND DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS IS DRIVING THE EUROPE TRANSFECTION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 TRANSIENT TRANSFECTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE TRANSFECTION MARKET IN 2021 & 2028
FIGURE 14 APPROVAL PROCESS FOR GENE THERAPY IN CHINA
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE TRANSFECTION MARKET
FIGURE 16 EUROPE TRANSFECTION MARKET: BY TYPE, 2020
FIGURE 17 EUROPE TRANSFECTION MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 18 EUROPE TRANSFECTION MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 19 EUROPE TRANSFECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 EUROPE TRANSFECTION MARKET: BY METHODS, 2020
FIGURE 21 EUROPE TRANSFECTION MARKET: BY METHODS, 2020-2028 (USD MILLION)
FIGURE 22 EUROPE TRANSFECTION MARKET: BY METHODS, CAGR (2021-2028)
FIGURE 23 EUROPE TRANSFECTION MARKET: BY METHODS, LIFELINE CURVE
FIGURE 24 EUROPE TRANSFECTION MARKET: BY METHODS, 2020
FIGURE 25 EUROPE TRANSFECTION MARKET: BY METHODS, 2020-2028 (USD MILLION)
FIGURE 26 EUROPE TRANSFECTION MARKET: BY METHODS, CAGR (2021-2028)
FIGURE 27 EUROPE TRANSFECTION MARKET: BY METHODS, LIFELINE CURVE
FIGURE 28 EUROPE TRANSFECTION MARKET: BY PRODUCT, 2020
FIGURE 29 EUROPE TRANSFECTION MARKET: BY PRODUCT, 2020-2028 (USD MILLION)
FIGURE 30 EUROPE TRANSFECTION MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 31 EUROPE TRANSFECTION MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 32 EUROPE TRANSFECTION MARKET: BY ORGANISM, 2020
FIGURE 33 EUROPE TRANSFECTION MARKET: BY ORGANISM, 2020-2028 (USD MILLION)
FIGURE 34 EUROPE TRANSFECTION MARKET: BY ORGANISM, CAGR (2021-2028)
FIGURE 35 EUROPE TRANSFECTION MARKET: BY ORGANISM, LIFELINE CURVE
FIGURE 36 EUROPE TRANSFECTION MARKET: BY TYPES OF MOLECULE, 2020
FIGURE 37 EUROPE TRANSFECTION MARKET: BY TYPES OF MOLECULE, 2020-2028 (USD MILLION)
FIGURE 38 EUROPE TRANSFECTION MARKET: BY TYPES OF MOLECULE, CAGR (2021-2028)
FIGURE 39 EUROPE TRANSFECTION MARKET: BY TYPES OF MOLECULE LIFELINE CURVE
FIGURE 40 EUROPE TRANSFECTION MARKET: BY APPLICATION, 2020
FIGURE 41 EUROPE TRANSFECTION MARKET: BY APPLICATION, 2020-2028 (USD MILLION)
FIGURE 42 EUROPE TRANSFECTION MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 43 EUROPE TRANSFECTION MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 44 EUROPE TRANSFECTION MARKET: BY STAGES, 2020
FIGURE 45 EUROPE TRANSFECTION MARKET: BY STAGES, 2020-2028 (USD MILLION)
FIGURE 46 EUROPE TRANSFECTION MARKET: BY STAGES, CAGR (2021-2028)
FIGURE 47 EUROPE TRANSFECTION MARKET: BY STAGES, LIFELINE CURVE
FIGURE 48 EUROPE TRANSFECTION MARKET: BY END USER, 2020
FIGURE 49 EUROPE TRANSFECTION MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 50 EUROPE TRANSFECTION MARKET: BY END USER, CAGR (2021-2028)
FIGURE 51 EUROPE TRANSFECTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 52 EUROPE TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 53 EUROPE TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 54 EUROPE TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 55 EUROPE TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 1 EUROPE TRANSFECTION MARKET: SNAPSHOT (2020)
FIGURE 2 EUROPE TRANSFECTION MARKET: BY COUNTRY (2020)
FIGURE 3 EUROPE TRANSFECTION MARKET: BY COUNTRY (2021 & 2028)
FIGURE 4 EUROPE TRANSFECTION MARKET: BY COUNTRY (2020 & 2028)
FIGURE 5 EUROPE TRANSFECTION MARKET: BY TYPE (2021-2028)
FIGURE 6 EUROPE TRANSFECTION MARKET: COMPANY SHARE 2020 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
